Logo image
Back
Clinical characteristics at diagnosis of patients who survive more than 5 years after diagnosis of metastatic colorectal cancer (mCRC)
Abstract   Peer reviewed

Clinical characteristics at diagnosis of patients who survive more than 5 years after diagnosis of metastatic colorectal cancer (mCRC)

Manuel Cruz Abrahao, Joao Paulo Velloso Medrado Santos, Thayse Pavan, Paulo M. Hoff, Artur Katz, Jorge Sabbaga, Fernanda Azevedo, Daniela Freitas, Daniel F. Saragiotto and Frederico Costa
Journal of clinical oncology, Vol.31(15_suppl), pp.e14590-e14590
05/20/2013
DOI: 10.1200/jco.2013.31.15_suppl.e14590

View Online

Abstract

Abstract only e14590 Background: Metastatic disease is a prevalent condition that will develop in close to 40% of patients diagnosed with colorectal cancer. Most patients with mCRC will eventually die due to tumor related causes. Advances in surgical intervention and systemic therapies have significantly increased the life expectancy of such patients. Only, a minority of patients with mCRC will survive more than 5 years. The clinical characteristics at initial presentation have not been reported in the era of novel therapies. Methods: All medical charts from patients with colorectal cancer consulted at HSL from 1998 to 2012 were reviewed. Patients with synchronous or metachronous mCRC were selected and only patients who survived more than 5 years from the date of confirmed diagnosis of metastasis were included in the analysis. Results: 1,406 patients with colorectal cancer were reviewed and 793 patients (56,4%) were confirmed with mCRC. 57 of them survived more than 5 years (4%). The clinical characteristics at diagnosis are presented in the Table. 93% of the patients are alive with a median follow-up of 88 months. 91% of them remained ECOG 0/1. The reported objective response to systemic therapy was 97% in first line, 79% in second line, and 66% in third line. All patients with liver only metastasis underwent surgery and 36% are disease-free with median follow-up of 107 months. Conclusions: Patients with mCRC who survived more than 5 years represent a distinctive group not identified by clinical characteristics at the initial presentation. They are highly sensitive to systemic therapy and this seems to be a good marker for patients who will have long survival. Our next step will be to attempt to identify molecular markers for those patients. [Table: see text]

Details

Metrics

Logo image